Evaluation of Th17 and Treg cytokines in patients with unexplained recurrent pregnancy loss.
T helper 17 cells
Tregs
immunological responses
unexplained recurrent pregnancy loss
Journal
Journal of clinical and translational research
ISSN: 2424-810X
Titre abrégé: J Clin Transl Res
Pays: Singapore
ID NLM: 101667205
Informations de publication
Date de publication:
29 Jun 2022
29 Jun 2022
Historique:
received:
18
05
2021
revised:
28
11
2021
accepted:
07
04
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
The Th17/Treg balance in peripheral blood and reproductive tissues may have a role in the etiology of unexplained recurrent pregnancy loss (URPL). In this study, we evaluated the major cytokine of Treg cells transforming growth factor-beta (TGF-β), and their specific transcription factor Forkhead box P3 (FOXP3), as well as the most highlighted cytokine of Th17 cells (interleukin [IL]-17A) in both URPL patients and healthy women. Samples were extracted from the peripheral blood, endocervix, endometrium, and vagina of 14 patients with URPL and 12 normal non-pregnant women as a control (normal) group. Quantitative reverse transcription polymerase chain reaction was used to determine gene expression. Enzyme-linked immunosorbent assay was used to determine the levels of cytokines in the serum and cervicovaginal fluid. We found that in the URPL group, FOXP3 gene expression was considerably higher in peripheral blood than in the normal group ( Lower TGF-β levels in the cervicovaginal fluid of patients compared to controls may be related with increased IL-17 and FOXP3 mRNA levels in patients with URPL. Dysregulation of local immune responses in reproductive tissues may represent dysregulation of systemic regulatory immunological responses in the pathogenesis of URPL. Dysregulation of immune responses may play a role in the pathogenesis of URPL at least in some patients with URPL. We conclude that the breakdown of tolerance in the local immune responses is more critical than the breakdown of tolerance in systemic tolerance in the pathogenesis of URPL. Therefore, modulating immune responses in the endometrium and decidua may be the focus of future therapeutic approaches in URPL. The impact of seminal plasma on the expansion of Tregs may provide a novel therapeutic intervention that has already been used in assisted reproductive technologies. Therefore, we suggest that transvaginal TGF-β in women with URPL may induce maternal tolerance which leads to the successful pregnancy.
Sections du résumé
Background and Aim
UNASSIGNED
The Th17/Treg balance in peripheral blood and reproductive tissues may have a role in the etiology of unexplained recurrent pregnancy loss (URPL). In this study, we evaluated the major cytokine of Treg cells transforming growth factor-beta (TGF-β), and their specific transcription factor Forkhead box P3 (FOXP3), as well as the most highlighted cytokine of Th17 cells (interleukin [IL]-17A) in both URPL patients and healthy women.
Methods
UNASSIGNED
Samples were extracted from the peripheral blood, endocervix, endometrium, and vagina of 14 patients with URPL and 12 normal non-pregnant women as a control (normal) group. Quantitative reverse transcription polymerase chain reaction was used to determine gene expression. Enzyme-linked immunosorbent assay was used to determine the levels of cytokines in the serum and cervicovaginal fluid.
Results
UNASSIGNED
We found that in the URPL group, FOXP3 gene expression was considerably higher in peripheral blood than in the normal group (
Conclusion
UNASSIGNED
Lower TGF-β levels in the cervicovaginal fluid of patients compared to controls may be related with increased IL-17 and FOXP3 mRNA levels in patients with URPL. Dysregulation of local immune responses in reproductive tissues may represent dysregulation of systemic regulatory immunological responses in the pathogenesis of URPL.
Relevance for Patients
UNASSIGNED
Dysregulation of immune responses may play a role in the pathogenesis of URPL at least in some patients with URPL. We conclude that the breakdown of tolerance in the local immune responses is more critical than the breakdown of tolerance in systemic tolerance in the pathogenesis of URPL. Therefore, modulating immune responses in the endometrium and decidua may be the focus of future therapeutic approaches in URPL. The impact of seminal plasma on the expansion of Tregs may provide a novel therapeutic intervention that has already been used in assisted reproductive technologies. Therefore, we suggest that transvaginal TGF-β in women with URPL may induce maternal tolerance which leads to the successful pregnancy.
Identifiants
pubmed: 35813894
pii: jctres.08.202203.001
pmc: PMC9260344
Types de publication
Journal Article
Langues
eng
Pagination
256-265Informations de copyright
Copyright: © 2022 Whioce Publishing Pte. Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. The authors alone are responsible for the content of this manuscript.
Références
J Immunotoxicol. 2015;12(4):317-21
pubmed: 26269135
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1973-8
pubmed: 25973091
Methods Mol Biol. 2015;1275:31-56
pubmed: 25697650
Iran Biomed J. 2020 Feb 23;24(5):295-305
pubmed: 32429643
Int J Fertil Steril. 2014 Apr;8(1):59-66
pubmed: 24695956
Am J Reprod Immunol. 2010 Jul 1;64(1):4-11
pubmed: 20219063
Immunol Res. 2007;39(1-3):62-78
pubmed: 17917056
Nat Rev Immunol. 2008 Jul;8(7):523-32
pubmed: 18566595
Biol Reprod. 2013 Jun 20;88(6):155
pubmed: 23553431
Fertil Steril. 2017 Jan;107(1):64-65
pubmed: 27887715
Nature. 2006 May 11;441(7090):235-8
pubmed: 16648838
Fertil Steril. 2010 Nov;94(6):2244-7
pubmed: 20056219
Placenta. 2015 Feb;36(2):226-31
pubmed: 25499308
Nat Immunol. 2004 Mar;5(3):266-71
pubmed: 14758358
Immunol Res. 2008;41(2):87-102
pubmed: 18172584
J Immunol. 2015 Jan 1;194(1):113-24
pubmed: 25452562
Arthritis Rheum. 2006 May;54(5):1491-500
pubmed: 16646030
Hum Reprod Update. 2009 Sep-Oct;15(5):517-35
pubmed: 19279047
J Immunol. 2008 Apr 15;180(8):5737-45
pubmed: 18390759
Immunol Lett. 2014 Nov;162(1 Pt A):41-8
pubmed: 24996040
Turk J Med Sci. 2015;45(4):837-41
pubmed: 26422855
Eur J Clin Nutr. 2016 Sep;70(9):1004-8
pubmed: 27222154
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8
pubmed: 21118827
Front Immunol. 2019 Mar 26;10:573
pubmed: 30972068
Hypertension. 2018 Jul;72(1):177-187
pubmed: 29785960
Annu Rev Pathol. 2019 Jan 24;14:185-210
pubmed: 30183507
Cytokine. 2018 Aug;108:115-119
pubmed: 29602154
J Clin Transl Res. 2015 Dec 17;1(3):180-189
pubmed: 30873453
Curr Mol Pharmacol. 2020;13(4):306-317
pubmed: 32124705
Lancet Diabetes Endocrinol. 2018 Sep;6(9):725-732
pubmed: 29859909
Reprod Biol Endocrinol. 2014 Aug 03;12:74
pubmed: 25086467
Immunology. 2004 May;112(1):38-43
pubmed: 15096182
Curr Opin Pharmacol. 2010 Aug;10(4):482-96
pubmed: 20427238
J Reprod Immunol. 2010 Mar;84(2):164-70
pubmed: 20106535
Lancet. 2006 Aug 12;368(9535):601-11
pubmed: 16905025
Front Immunol. 2019 Oct 18;10:2317
pubmed: 31681264
J Reprod Immunol. 2016 Aug;116:13-22
pubmed: 27128988
Am J Reprod Immunol. 2012 Apr;67(4):304-10
pubmed: 22364212
Front Genet. 2021 Dec 06;12:779494
pubmed: 34956328
Nat Immunol. 2003 Apr;4(4):330-6
pubmed: 12612578
Immunol Res. 2016 Jun;64(3):785-90
pubmed: 26754761
Bioessays. 2002 Oct;24(10):904-14
pubmed: 12325123
Nat Rev Drug Discov. 2012 Oct;11(10):763-76
pubmed: 23023676
Mol Hum Reprod. 2006 May;12(5):301-8
pubmed: 16574699
Reprod Sci. 2017 Jul;24(7):1014-1024
pubmed: 27834288
Sci Rep. 2019 Aug 23;9(1):12314
pubmed: 31444404
Mucosal Immunol. 2017 Sep;10(5):1097-1107
pubmed: 28401937
Front Immunol. 2019 Nov 22;10:2739
pubmed: 31824513
J Cell Physiol. 2018 Feb;233(2):830-848
pubmed: 28059453
Iran J Allergy Asthma Immunol. 2019 Apr 01;18(2):163-172
pubmed: 31066252
Brain Behav Immun. 2011 Jul;25(5):863-71
pubmed: 20854892
Immunology. 2018 Sep;155(1):24-35
pubmed: 29682722
IUBMB Life. 2020 Dec;72(12):2572-2583
pubmed: 33107698
Cureus. 2018 Jun 5;10(6):e2741
pubmed: 30087817
Scand J Immunol. 2009 Oct;70(4):326-36
pubmed: 19751267
Obstet Gynecol Sci. 2019 Jul;62(4):212-223
pubmed: 31338338
Int Immunopharmacol. 2021 Jan;90:107195
pubmed: 33278746
Am J Reprod Immunol. 2011 May;65(5):503-11
pubmed: 21029245
Hum Reprod. 2011 Nov;26(11):2964-71
pubmed: 21926059
J Immunotoxicol. 2016 May;13(3):286-300
pubmed: 27043356
J Clin Transl Res. 2021 Jul 16;7(4):450-455
pubmed: 34667891
Reprod Fertil Dev. 2015 May 14;:
pubmed: 25969999
J Clin Immunol. 2000 Nov;20(6):453-7
pubmed: 11202235
Clin Immunol. 2010 Sep;136(3):432-41
pubmed: 20542739
Cold Spring Harb Perspect Biol. 2017 Jun 1;9(6):
pubmed: 28108486
Immunol Rev. 2011 May;241(1):260-8
pubmed: 21488902
Mol Hum Reprod. 2004 May;10(5):347-53
pubmed: 14997000
Fertil Steril. 2008 Mar;89(3):656-61
pubmed: 17543960
Hum Reprod. 2010 Oct;25(10):2591-6
pubmed: 20685755
Autoimmun Rev. 2014 Jun;13(6):668-77
pubmed: 24418308
Am J Reprod Immunol. 2013 Nov;70(5):398-411
pubmed: 23656517
J Clin Transl Res. 2016 Sep 15;2(3):84-90
pubmed: 30873466
Ann Hepatol. 2017 Oct 16;16(6):832-834
pubmed: 29055914
J Reprod Immunol. 2019 Feb;131:30-35
pubmed: 30634133
Clin Dev Immunol. 2012;2012:896458
pubmed: 21876709
J Clin Transl Res. 2021 Sep 20;7(5):648-656
pubmed: 34778595
J Clin Transl Res. 2021 May 27;7(3):333-376
pubmed: 34239993
J Clin Transl Res. 2021 Jul 30;7(4):485-500
pubmed: 34541363
APMIS. 2011 Sep;119(9):597-604
pubmed: 21851417
Am J Reprod Immunol. 1995 Jul;34(1):52-64
pubmed: 7576131
Hum Reprod. 2014 Feb;29(2):208-19
pubmed: 24277747
Am J Clin Exp Immunol. 2013 Oct 16;2(3):222-33
pubmed: 24179730